Is there a link between CLL and stomach pain?

Is there a link between chronic lymphocytic leukemia and stomach pain?

This article was originally posted on Medical News Today 

Chronic lymphocytic leukemia (CLL) is a type of blood cancer. It affects lymphocytes, a type of immature white blood cell that the body produces in the bone marrow.

People with CLL may experience discomfort, swelling, and pain in the abdomen if their spleen enlarges. In rare cases, CLL can also affect mucosal tissues, such as those lining the gastrointestinal (GI) tract.

This article discusses the link between CLL and stomach pain in more detail. It also looks at ways to prevent and treat CLL, the other possible symptoms, and the outlook for people with this condition.

People with CLL may experience various symptoms involving the abdomen or stomach, such as:

  • discomfort, pain, or tenderness
  • feeling full after eating small amounts of food
  • swelling
  • diarrhea or vomiting
  • abdominal cramping
  • loss of appetite
  • unexplained weight loss

In most cases, people with CLL do not experience abdominal symptoms due to the disease until it progresses and becomes more severe.

Research suggests that CLL infiltrates and affects the GI tract in about 5.7–13% of cases. When CLL affects the GI tract, doctors may call it Richter’s syndrome.

Why might stomach pain occur?

People with CLL may experience abdominal swelling, discomfort, and tenderness as a result of their spleen becoming larger. Less commonly, they may also feel full after eating small amounts of food, as the spleen can press on the stomach, making it smaller and able to hold less.

In rare cases, CLL infiltrates the lining of the GI tract, causing inflammation and ulcers or open wounds. People may experience symptoms similar to those of inflammatory bowel disease (IBD) and malabsorption disorders. These symptoms may include diarrhea, nausea, vomiting, abdominal pain and cramping, and unintentional weight loss.

CLL overview

CLL is cancer that develops in lymphocytes, which are white blood cells that form in the bone marrow and help fight infection.

Lymphocytes make up most of the lymph tissues in the lymph nodes, thymus gland, adenoids, tonsils, and spleen. They are also present in the GI tract, bone marrow, and respiratory system.

CLL is a type of leukemia that develops gradually over time.

Other symptoms of CLL

About 50–75% of people with CLL do not experience noticeable symptoms. Due to this, doctors diagnose most people with CLL during routine blood work.

The symptoms of CLL often begin when the cancerous cells crowd out healthy cells in the bone marrow or migrate to other organs or tissues. When symptoms first appear, they are typically mild, but they then become increasingly severe. CLL can cause many nonspecific symptoms, so a person may feel as though they have a cold or the flu.

Possible symptoms of CLL that do not relate to the abdominal area include:

  • swollen lymph nodes
  • frequent infections that are difficult to recover from
  • unexplained exhaustion or weakness
  • unexplained breathlessness or breathing issues
  • excessive or abnormal bruising
  • nosebleeds and heavy periods
  • bone pain
  • night sweats
  • low grade fever
  • jaundice, which is a yellowing of the mucous membranes, whites of the eyes, or skin

To continue reading this article on Medical News Today 


CLL Advocates Newsletter Issue 11

CLL Advocates Newsletter Issue 11

Dear Friends of CLLANZ

Skin infection (cellulitis) and CLL – a cautionary tale

Cellulitis is an infection of the skin, most commonly of the legs. It is usually due to bacteria. It commonly arises when the integrity of the skin is breached by a penetrating injury, often in the context of a pre-existing condition, such as diabetes, and conditions where immunity is impaired, such as CLL.

Cellulitis is the second most common primary site causing severe infection in patients with CLL (lower respiratory tract infections are the most common). It is often associated with sepsis/septicemia; when this happens, mortality is about 25% one month on from the episode of cellulitis. So awareness of what cellulitis is, and prompt antibiotic treatment thereof can save lives.

Professionally and theoretically, I have always been concerned about the risks of cellulitis, but in practice I’ve always led a physically active lifestyle, acquiring numerous skin injuries in the process. So it’s perhaps surprising that I hadn’t ever got cellulitis.

That all changed recently, when I had a penetrating injury of my left leg by a stick. Twelve hours later, I awoke in the night feeling very unwell, with a red, swollen, and painful leg. I was admitted to hospital for five days of intravenous antibiotics (blood cultures were positive for E. coli), with a good response, and was sent home on oral antibiotics.

About a week later, the infection recurred, despite oral antibiotics, and I again felt very unwell. I was readmitted to hospital, the first few days of this period being in ICU/HDU because of my level of unwellness. Blood cultures were again positive for E. coli. This time, I was an inpatient for a total of fifteen days; IV antibiotics for all that time, then a further week of IV antibiotics as an outpatient, after discharge. This seems to have done the trick, and I am currently back to where I was pre-leg injury, health-wise.

So, for those with CLL, please look after your skin, particularly on your legs. Wear gumboots and other protective clothing when in the outdoors, seek prompt medical advice/treatment for any skin injuries, and keep a careful eye on such injuries. Sepsis can be serious/fatal quite quickly.

I for one have certainly adopted a change in approach to looking after my skin as a consequence of this episode.

Best wishes

Neil Graham


Attempting to target the tumor microenvironment leads the way to an array of potential targetable pathways in the disease..

According to the researchers, attempting to target the tumor microenvironment leads the way to an array of potential targetable pathways in the disease, including through the use of combination therapy.

A variety of treatments spanning different treatment classes are being studied for use in chronic lymphocytic leukemia (CLL) in an attempt to target the tumor microenvironment environment (TME) of CLL, which attributes to the disease’s genetic complexity. In a recent review, researchers outlined the potential of the approach.

According to the researchers, attempting to target the TME, which is essential for the development, growth, and survival of malignant B-cell clone in CLL, leads the way to an array of potential targetable pathways in the disease, including through the use of combination therapy.

“It is becoming evident that improving clinical responses (residual and progressive disease), overcoming toxicity, infection risk, as well as drug resistance, likely require strategies aimed at reshaping the immunosubversive, pro-tumor TME state,” explained the researchers. “Our improved understanding of the direct and indirect CLL-TME modulations by novel therapeutic agents in recent years provides a unique opportunity to optimize CLL treatment with strategic drug combinations that target multiple CLL-TME interactions to achieve therapeutic synergy while controlling toxicity.”

Combinations include adding venetoclax to ibrutinib, which has showed promise for improving the duration of remissions, as well as adding the PI3K inhibitor duvelisib to venetoclax to improve the sensitivity of CLL cells. The latter is currently being tested in clinical trials.

Venetoclax has also showed promise in combination with anti-CD20 antibodies, with the combination demonstrating in vitro an improvement in the phagocytosis of CLL cells by macrophages while reversing resistance to venetoclax.

“Interestingly, although venetoclax plus anti-CD20 treatment produces impressive clinical responses in clinical trials, a recent retrospective study including real-world data demonstrated comparable efficacy between venetoclax as a single agent and venetoclax plus anti-CD20 combination treatment in high risk relapsed/refractory CLL patients,” wrote the researchers, “Thus, further validating prospective studies are warranted to determine whether the addition of an anti-CD20 antibody to venetoclax is truly necessary.”

On the other hand, adding an anti-CD20 antibody to ibrutinib also seemed to result in faster remissions and lower residual disease but was found to not improve profession-free survival.

This article was originally posted AJMC

Research has also focused on chimeric antigen receptor (CAR) T-cell therapy, as identifying treatment regimens that overcome T-cell dysfunction and improve the efficacy of T-cell-based treatments and immune checkpoint blockade represent some of the biggest challenges in CLL.

Early research has indicated that adding ibrutinib to CAR T-cell function concurrently may enhance CAR T-cell function. In one clinical pilot study, adding concurrent ibrutinib to CD19-targeted CAR T-cell therapy showed strong response rates in patients with relapsed/refractory CLL. The treatment combination also showed lower toxicities than CAR T-cell therapy alone.

Reference

Svanberg R, Janum S, Patten P, Ramsay A, Niemann C. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica. Published online April 22, 20

To continue reading this article on AJMC


Medical specialist says Pharmac 'wish list' is a 'necessity list'

Medical specialist says Pharmac 'wish list' is a 'necessity list'

Health expert discusses Pharmac’s funding option list

Watch the video here. Credits: The AM Show.

For the first time there is transparency with Pharmac.

The released ‘Options for Investment’ list, provided to Newshub, shows 73 medicines yet to be funded. Should the Government bite the bullet and invest in these life saving recommendations?

Former Executive Director of Association of Salaried Medical Specialists and health commentator Ian Powell joined The AM Show on Friday morning.

 


CLL Advocates Newsletter Issue 10

CLL Advocates Newsletter Issue 10

Dear Friends of CLLANZ

It was very interesting to learn in the news this week of Pharmac’s ‘wish list’ of 73 medicines it would like to pay for, if it had the budget to do so.  It’s the first time Pharmac has released figures for what it calls its ‘options for investment’ list. The cost of funding them would be $417,670,000.00. Newshub got the story from an Official Information Act request – see it here, and see Pharmac’s formal response here.

The wish list is separated into proposals (118) and medicines (73), (as some medicines treat several illnesses) and it comes with a breakdown of how long they’ve been waiting.  Although the list hasn’t been released, we expect Ibrutinib to be on it, as one of the 14 (of the total of 73) that have been waiting the longest, i.e. for 6+ years.

The timing of this is interesting, coming as it does in the lead-up to the Budget (May 20), and with Health Minister Andrew Little confirming to Newshub that any additional funding for Pharmac comes down to a political decision. That reality is also reflected in the government’s decision to exclude funding from the ‘independent’ review of Pharmac that is currently underway.

Filling the budget hole to fund the 73 ‘wish list’ medicines would mean a 40% increase in Pharmac’s funding, an increase that would go some way to bringing us into to line with Australia, the UK, Canada, etc.  We don’t know what Pharmac’s bid has been for this year’s Budget, but last year they didn’t ask for any more money at all!

We in CLLANZ have worked hard over recent years through petitions, submissions, engaging with media, marching on Parliament, appearances at select committees, and actively engaging with Pharmac to advocate for access for CLL patients to Ibrutinib, among other treatments, as well as treatment pathway reforms, and faster, more transparent funding decisions. We’re very proud to have been part of the push to reform Pharmac, which is now seen as losing the PR battle.

We hope this work will bear fruit in the coming Budget, but in the meantime we intend to continue our advocacy as vigorously as possible.  In this regard I warmly encourage you to support the current ‘Lie Down For Life’ campaign running nationwide on 12 May by Patient Voice Aotearoa. And if you haven’t already signed their petition to Reform Pharmac and Double its Budget, you can still do so here. This will be presented to Parliament on 12 May, the same day as we Lie Down For Life!

Kia kaha

Neil Graham


Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL Population

Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL Population

This article was originally posted on Targeted Oncology 

William G. Wierda, MD, PhD, D. B. Lane Cancer Research Distinguished Professor, section chief of Chronic Lymphocytic Leukemia, and center medical director in the Department of Leukemia, Division of Cancer Medicine, and executive medical director of The University of Texas MD Anderson Cancer Center, discusses the synergy between ibrutinib (Imbruvica) and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Ibrutinib, a Bruton’s Kinase inhibitor (BTK), inhibits a molecule that is downstream of the B-cell receptor–signaling pathway, BTK. It was approved for use in patients with relapsed disease first and then as frontline treatment in CLL. Wierda says it is very effective and active, including in patients who have been considered high-risk; these patients are defined as those who harbor 17p deletions or TP53 mutations.

Venetoclax is also a small molecule inhibitor that inhibits BCL-2. When patients’ CLL cells are exposed to venetoclax and BCL-2 is inhibited with this agent, it pushes the cells into apoptosis and causes cell death of the CLL.

Ibrutinib is very effective at managing this disease, according to Wierda. Clinically, it works well in shrinking lymph node size in these patients. Many of those who respond achieve a partial response. This means there is still some measurable disease, usually in the bone marrow or blood. Wierda says venetoclax is highly effective at killing CLL cells and is very potent at killing cells in the blood and bone marrow. However, it’s less active when it comes to shrinking nodal disease.

To continue reading this article on Targeted Oncology  


CLL Advocates Newsletter Issue 9

CLL Advocates Newsletter Issue 9

Dear Friends,

I and two colleagues are in the final process of submitting for publication a paper on second primary malignancies (SPM) in NZers with CLL. I have mentioned this briefly previously in my newsletter and I will let you know when the paper is published. The NZ experience of SPM in CLL has not been studied before.

The commonest type of SPM in NZers with CLL was skin cancer in its various forms, which accounted for over 80% of SPMs. One of the bottom line messages from the study therefore was to use skin protection from the sun for prevention, and have a skin check twice a year if you have CLL.

And reflecting on prevention and early detection, we all also need to focus on a holistic approach to health issues and healthy living, oncology patients perhaps even more so, as well as accessing treatment for our CLL – the latter potentially being a distraction from a broad approach to the way we look after ourselves.

You will all be familiar with these lifestyle components, including the following:

  • Keep yourself lean, and, if you are overweight , take steps to get a healthier BMI (obesity in recent times has been shown to be a major element in risk of malignant disease)
  • Don’t smoke
  • Take alcohol in moderation, if you drink it
  • Exercise regularly (studies in recent times have shown extensive health benefits from exercising)
  • Keep happy, and keep your stress levels down
  • Eat healthily
  • Lead a balanced existence

In my career as an internal medicine specialist, I have always tried to encourage patient to focus on a broad approach to their disease, not just the main active problem, and have seen how much of a difference this approach can make.

Best wishes

Neil Graham


Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL

Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL

This article was originally published on CancerNetwork

The combination of ublituximab plus ibrutinib (Imbruvica) led to a statistically higher overall response rate while maintaining the tolerable safety profile over ibrutinib monotherapy to treat patients with relapsed or refractory high-risk chronic lymphocytic leukemia (CLL).

According to data published in The Lancet Haematology from the phase 3, multicenter, GENUINE (NCT02301156) trial, these findings support the addition of ublituximab to Bruton tyrosine kinase (BTK) inhibitors as treatment for patients with this class of CLL.

“Clinically meaningful improvements in overall response rate, complete response, and MRD negative response were observed and translated into improved progression­free survival,” wrote the investigators. “These findings indicate the benefit of adding the next­generation anti­CD20 antibody ublituximab to ibrutinib in patients with relapsed and refractory high-risk chronic lymphocytic leukaemia.”

The overall response rate was 83% of patients in the ublituximab plus ibrutinib group and 65% of patients in the ibrutinib group (P = .020) after a median follow-up of 41.6 months (IQR 36.7–47.3).

While the safety profile consisted mostly of grade 1 or 2 adverse events, neutropenia (19% of patients in the combination group vs 12% in the control group), anemia (8% vs 9%, respectively), and diarrhea (10% vs 5%) were common grade 3 and 4 adverse events among the population of interest.

More, common serious adverse events included pneumonia (10% with ublituximab vs 7% with ibrutinib only), atrial fibrillation (7% vs 2%, respectively), sepsis (7% vs 2%), and febrile neutropenia (5% vs 2%).

Two patients from the ublituximab plus ibrutinib group and 5 patients and from the ibrutinib group died from adverse events. Only 1 death (cardiac arrest) from the ibrutinib group was considered treatment-related.

To continue reading this article on CancerNetwork


Webinar: The current CLL treatment landscape and advocating for your care

The Current CLL Treatment Landscape and Advocating for Your Care

Overview

Join us for a virtual town hall meeting for chronic lymphocytic leukemia (CLL) patients and family members on Saturday, March 20, 2021 starting at 10 am CT/11 am ET. – 5am, Sunday 11 March NZST

This 3-hour program will take you through the current treatment landscape of CLL, including the latest news in research, state-of-the-art testing and personalized care. Our speakers will offer advice on advocating for the best of care, staying informed and playing an active role in your treatment journey. Join our hosts Carol Preston, Andrew Schorr and Michele Nadeem-Baker for this informative session on living with CLL. Our special guests include Shuo Ma, MD, PhD, and Nurse Practitioner Jennifer Boyer, MSN APRN NP-C, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, as well as Deborah M. Stephens, DO, of the Huntsman Cancer Institute at University of Utah and Jane Dabney, LISW-S, OSW-C, Senior Oncology Social Worker at Cleveland Clinic.

Agenda

10:00-10:30 am CT – Introduction: Information for those who are newly diagnosed or beginning their treatment journey. Learn about the stages of CLL and questions to ask your doctor.

10:30-10:45 am CT – CLL and COVID-19: What should patients know about the COVID vaccine? Is it safe to start or resume treatment right now? Get the latest updates on COVID-19.

10:45-11:30 am CT – The Treatment Landscape: Learn about the current CLL treatment landscape, including the latest news in research, state-of-the-art testing and options for personalized care.

11:30-11:45 am CT – Break

11:45-12:30 pm CT – Being Your Own Advocate: Experts and patient guests discuss how patients and care partners can advocate for the best of care, stay informed, and play a more active role in their treatment.

12:30-1:00 pm CT – Q&A

Send us your questions: cll@patientpower.info

Learn more here and register to attend


CLL Can Leave You Immunocompromised. Here’s How to Manage

CLL Can Leave You Immunocompromised. Here’s How to Manage

This article was originally posted by Healthline

  • Chronic lymphocytic leukemia (CLL) is a type of cancer that attacks white blood cells, affecting your body’s ability to fight off infection.
  • CLL leaves you immunocompromised, increasing your risk of infection, other cancers, autoimmune conditions, and severe complications from COVID-19.
  • Taking steps to stay healthy and boost immunity can help you stay well with CLL.

Your bone marrow plays an important role in your body. It produces versatile stem cells that become specific types of blood cells. Red blood cells transport oxygen to the body, platelets stop bleeding, and white blood cells combat infection to keep you healthy.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts in your bone marrow. CLL changes your infection-fighting white blood cells and interferes with how they function. As a result, CLL weakens the immune system.

Read on for more information, plus tips for how to manage being immunocompromised when you have CLL.

CLL and your immune system

There are several types of white blood cells, but lymphocytes are the ones primarily involved in CLL.

Healthy lymphocytes protect you against viral, bacterial, and fungal infections that can make you sick. When you have CLL, your body produces abnormal lymphocytes called leukemia cells, which don’t fight infection as well as lymphocytes.

With CLL, your bone marrow still produces normal white blood cells, but the leukemia cells multiply faster and live longer than the healthy ones. As they reproduce, these leukemia cells take over space in your bone marrow, leaving less room for healthy white blood cells. Because the leukemia cells don’t fight infection well, as their numbers increase, your immunity decreases.

To continue reading this article on Healthline